ATYR

aTYR is a single-asset clinical-stage biotech whose entire value rests on efzofitimod, and in September 2025 the pivotal EFZO-FIT Phase 3 sarcoidosis study missed its primary endpoint: change in mean daily oral corticosteroid dose was 2.79 mg for the 5.0 mg/kg arm vs 3.52 mg for placebo, p=0.3313. Because the statistical plan was hierarchical, everything positive management now cites (KSQ-Lung p=0.0479, FAS p=0.0226, KSQ-General Health p=0.0197) is explicitly 'nominal' — not a basis for approval. Management's own filing concedes the stock 'experienced a material decline' since the readout. A mid-April 2026 Type C FDA meeting will determine whether there is any regulatory path at all; until then the outcome is unknowable, which is the definition of avoid rather than a value setup.

The balance sheet turns a speculative bet into an urgent one. The company holds just $10.7M of cash and equivalents (current assets $80.2M) against an operating cash burn of $62.0M in FY2025 and R&D that actually rose 10.8% to $60.2M. Retained deficit is -$606M. The MD&A states outright they 'will need to raise additional capital or enter into strategic partnering relationships to fund operations,' and their primary tool — the Jefferies ATM — sold FY2025 shares at a weighted-average $4.94; at $0.59 that same program raises a fraction of the cash while diluting far harder. Shares already grew 10.3% last year. A raise into a depressed, post-failure stock is close to certain and deeply dilutive.